Amphion Innovations plc
Directors Dealings

London and New York, 26 March 2009 – Amphion Innovations plc (LSE: AMP) ("Amphion" or the "Company"), the developer of medical and technology businesses, today announces that Chief Executive Officer, Richard Morgan and President and Chief Financial Officer, Robert Bertoldi, who are also both Board members, have received New Ordinary Shares in lieu of cash compensation. Richard Morgan received 632,209 Ordinary Shares, bringing his total holdings of the Company to 23,426,266 representing 17.85 per cent of the Company’s enlarged issued ordinary share capital. Robert Bertoldi received 75,865 Ordinary Shares bringing his total holdings of the Company to 6,436,431 representing 4.90 per cent of the Company’s enlarged issued Ordinary Share capital.

In addition to the 708,074 Ordinary Shares issued to Richard Morgan and Robert Bertoldi, 166,903 Ordinary Shares were also issued to six employees of the Company as part of their incentive compensation. Admission of the 874,977 new Ordinary Shares, ranking pari passu, is expected on 2 April 2009. Following this allotment the total issued share capital of the Company will increase to 131,253,834 Ordinary Shares.

In addition, the Company has to date granted options to employees and Directors under the Share Option Scheme in respect of 7,875,000 Ordinary Shares. The Company is now proposing to grant options in respect of a further 1,925,000 Ordinary Shares at an issue price of 10.75 pence per Ordinary Share to certain employees and Directors which shall be exercisable from 24 March 2010 under the terms of the Share Option Scheme. This will include options in respect of 500,000 Ordinary Shares granted to Richard Morgan and 350,000 Ordinary Shares granted to Robert Bertoldi.

Richard Morgan also purchased 150,000 Ordinary Shares on 25 March 2009. Of this, 113,640 Ordinary shares in the Company were purchased at a price of 10 pence per share and 36,360 Ordinary Shares at 11 pence per share in the Company. Accordingly, Richard Morgan is now beneficially interested in 23,576,266 Ordinary Shares representing 17.97% of the Company’s issued Ordinary Share capital.

For further information please contact

Amphion Innovations plc
Charlie Morgan, Director of Communications
+1 (212) 210 6224

Cardew Group
Tim Robertson/ Jamie Milton/ Matthew Law
+44 20 7930 0777

Charles Stanley (Nominated Adviser)
Mark Taylor/ Freddy Crossley
+44 20 7149 6000

About Amphion Innovations plc
Amphion (LSE: AMP) builds shareholder value in high growth companies in the medical and technology sectors, by using a focused, hands-on company building approach, based on decades of experience in both the US and UK. Amphion has significant shareholding in 10 Partner Companies developing proven technologies targeting substantial commercial marketplaces, each in excess of $1 billion.    Each Partner Company is chosen with the goal of achieving an exit valuation in excess of $100 million.

On the web: